Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 ~2x weekly·189 episodes·Last published 2w ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 14 epsHosts
Not detected.
Recent guests
Recent episodes
Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease
Jun 9, 2026
25m 41s
Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer
Jun 5, 2026
19m 41s
David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World
Jun 5, 2026
20m 43s
Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge
Jun 5, 2026
18m 45s
Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer
May 26, 2026
54m 23s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/9/26 | Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease✨ | metabolic diseaseMASH Matters+3 | Hannele Yki-Järvinen | PeerVoice | — | MASHmetabolic disease+3 | — | 25m 41s | |
| 6/5/26 | Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer✨ | TROP2-Directed ADCsAdvanced Breast Cancer+3 | Javier Cortés, MD, PhDLaura Huppert, MD | PeerVoice | — | TROP2ADCs+3 | — | 19m 41s | |
| 6/5/26 | David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World✨ | Rapid ARTGuidelines+3 | David Alain Wohl, MD | — | — | Rapid ARTHIV+3 | — | 20m 43s | |
| 6/5/26 | Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge✨ | Surgical InterventionsSystemic Innovations+3 | Silvia Stacchiotti, MDMichiel van de Sande, MD, PhD | PeerVoice | — | Tenosynovial Giant Cell Tumoursurgical interventions+3 | — | 18m 45s | |
| 5/26/26 | Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer✨ | head and neck cancerrecurrent cancer+4 | Trisha Wise-Draper, MD, PhD | — | — | head and neck cancerrecurrent cancer+5 | — | 54m 23s | |
| 5/18/26 | Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional✨ | Hypertrophic CardiomyopathyCardiac Myosin Inhibition+3 | Anjali Tiku Owens, MD | — | — | Hypertrophic CardiomyopathyCardiac Myosin Inhibition+3 | — | 1h 20m 09s | |
| 5/18/26 | Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice✨ | gastroenterologyMASH+3 | Sven Francque, MD, PhD | — | — | MASHfibrosis+3 | — | 35m 42s | |
| 4/30/26 | Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?✨ | Factor XIa InhibitionSecondary Stroke Prevention+3 | Mike Sharma, MD, MSc, FRCPC | — | — | Factor XIaStroke Prevention+5 | — | 1h 15m 47s | |
| 4/29/26 | Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition✨ | secondary stroke preventionFactor XIa inhibition+3 | Xin Cheng, MD, PhD | — | — | stroke preventionFactor XIa+3 | — | 36m 53s | |
| 4/29/26 | Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can✨ | GastroenterologyMASH+3 | Javier Ampuero, MD, PhD | — | — | MASHGastroenterology+3 | — | 20m 02s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/29/26 | Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes✨ | immunomodulationtype 1 diabetes+3 | Colin M. Dayan, MA, MBBS, FRCP, PhD | — | — | immunomodulationtype 1 diabetes+3 | — | 1h 19m 25s | |
| 4/15/26 | Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum✨ | Thymidine Kinase 2 DeficiencyClinical Diagnosis+3 | Caterina Garone, MD, PhD | — | — | Thymidine Kinase 2Deficiency+3 | — | 27m 58s | |
| 3/25/26 | Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade✨ | Paroxysmal Nocturnal HaemoglobinuriaComplement Cascade+3 | Austin Kulasekararaj, MD, MRCP, FRCPath | — | — | Paroxysmal Nocturnal Haemoglobinuriacomplement cascade+3 | — | 29m 29s | |
| 3/6/26 | Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era✨ | SCLC treatmentimmunotherapy+3 | Jonathan W. Goldman, MDMisty Dawn Shields, MD, PhD | PeerVoice | — | SCLCimmunotherapy+3 | — | 40m 01s | |
| 2/25/26 | David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases | David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases | — | ||||||
| 2/25/26 | Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care? | Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care? | — | ||||||
| 2/4/26 | Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients | Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients | — | ||||||
| 1/7/26 | Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders? | Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders? | — | ||||||
| 1/7/26 | Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings | Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings | — | ||||||
| 12/31/25 | Jörn M. Schattenberg, MD - Cases in Contemporary MASH Management: Expert Insights on the Practical Integration of Disease-Specific Pharmacotherapy | Jörn M. Schattenberg, MD - Cases in Contemporary MASH Management: Expert Insights on the Practical Integration of Disease-Specific Pharmacotherapy | — | ||||||
| 12/23/25 | Naim Alkhouri, MD, FAASLD, DABOM - Don’t Wait, and Look Beyond Weight: The Growing Case for Urgent and Comprehensive Management of MASH | Naim Alkhouri, MD, FAASLD, DABOM - Don’t Wait, and Look Beyond Weight: The Growing Case for Urgent and Comprehensive Management of MASH | — | ||||||
| 12/17/25 | Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact | Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact | — | ||||||
| 12/16/25 | Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring? | Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring? | — | ||||||
| 12/16/25 | Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition | Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition | — | ||||||
| 12/16/25 | Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy | Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy | — | ||||||
Showing 25 of 200
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.